Interview with Michael Azrak, Managing Director, MSD South Africa
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Address: 15e Riley Road
Bedfordview 2008 ,South Africa
Tel: +27 11 087 0000
iNova Pharmaceuticals develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa, the Americas and other international markets.
iNova has a broad range of prescription medicines and consumer healthcare products in several therapy areas including pain management, weight management, allergy, sexual health, dermatology, cardiology and respiratory health.
Among the wide variety of products iNova offers in our commitment to improving people’s health and well being are Australian made and owned market leading brands Difflam™, Duro-Tuss™, Hiprex™, Metsal™ and Cal-Sup™. We are also proud to make available to patients and consumers Azep®, Eyezep®, ZepAllergy™ and Rinar™.
Our broad product range, available in pharmacies only, comes from a heritage of many years of innovation and, more recently, in-licensed products. Strict quality assurance and control procedures help to ensure iNova produces and markets brands meeting the most rigorous quality standards. Our products are prescribed by specialist health care providers and general practitioners across the Region and supported by pharmacy recommendation.
The availability of our marketed products and information we lawfully can provide varies among countries. This website contains information on products which is targeted to a wide range of audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Our international readers know about South Africa’s socio-economic relative achievements, considering the country joined the BRICS grouping last year and achieved the first Millennium Development Goal (MDG) that same year.…
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
See our Cookie Privacy Policy Here
